Skip to main content

Table 1 Included studies and baseline characteristics of the patients

From: Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome

Study code a Publication, first author, study acronym Year Study design Indication Number of patients Male gender (%) Mean age (years) Treatment duration (months) Follow-up (months)
01 Finkelstein Y. et al. [19] 2002 Multicenter, randomized, double blind PPS prevention 111 73 64.0 1 3
02 Imazio M. et al., CORE [20] 2005 Single center, randomized, open label PER recurrence 84 35 53.8 6 20
03 Imazio M. et al., COPE [21] 2005 Multicenter, randomized, open label PER first episode 120 45 56.9 3 24
04 Imazio M. et al., COPPS [22] 2010 Multicenter, randomized, double blind PPS prevention 360 66 65.7 1 19
05 Imazio M. et al., CORP [23] 2011 Multicenter, randomized, double blind PER recurrence 120 52.5 47.6 6 18
06 Imazio M. et al., ICAP [24] 2013 Multicenter, randomized, double blind PER first episode 240 60 52.1 3 22
07 Imazio M. et al., COPPS-2 (11) 2014 Multicenter, randomized, double blind PPS prevention 360 69 67.5 1 3,1
08 Imazio M. et al., CORP-2 (10) 2014 Multicenter, randomized, double blind PER recurrence 240 50 48.8 6 20
09 Meurin P. et al., POPE-2 (21) 2015 Multicenter, randomized, double blind PE post heart surgery 197 86 64.5 0.5 6
10 Izadi Amoli A. et al., [18] 2015 Single center, randomized, triple blind PE post heart surgery 149 60 57.4 0.5 1
  1. astudy code of the publications included in the meta-analysis
  2. PE pericardial effusion, PER pericarditis, PPS post-pericardiotomy syndrome